Dortmund and Lyon, February 4th, 2020

The Max Planck Institute of Molecular Physiology (MPI) and Edelris announce today the launch of a new research collaboration.

Under the terms of the agreement, the aim of the collaboration will be to identify novel ligands towards groundbreaking biological targets. The biological targets of interest will be selected and provided by the MPI and Edelris will dedicate a privileged access to its EDEN platform (Edelris Discovery ENgine) involving affinity selection screening and a 1M compounds deck inspired by natural products (from Edelris Keymical SpaceTM).

“The understanding of complex biological pathways requires the ability to selectively interact with protein surfaces or disrupt specific protein‐protein interactions.” commented Prof. Herbert Waldmann, Director, Chemical Biology at the Max Planck Institute of Molecular Physiology. “We have demonstrated that such an ambitious goal can be efficiently achieved by means of pseudo‐natural products (Pseudo‐NPs). The Edelris collection is uniquely positioned to that respect, and we look forward to using their deck and screening technologies against some of our most relevant targets.”

“We are thrilled to be part of this dynamic collaboration with this world‐renowned partner, using our unique technologies and distinctive compound libraries. The project team is highly focused towards solving the high scientific challenges we will be facing.” added Dr Jean‐Yves Ortholand, CEO of Edelris.

The terms of the agreement were not disclosed.

More news

{"acf_fc_layout":"postList","postList_model":{"ID":3651,"post_author":"5","post_date":"2023-09-05 09:18:27","post_date_gmt":"2023-09-05 07:18:27","post_content":"","post_title":"More news","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"more-news","to_ping":"","pinged":"","post_modified":"2023-11-20 08:54:07","post_modified_gmt":"2023-11-20 07:54:07","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.edelris.com\/?post_type=waz_post_template&p=3651","menu_order":35,"post_type":"waz_post_template","post_mime_type":"","comment_count":"0","filter":"raw"},"postList_post_type":"actualites","postList_category_post":false,"postList_category_actualites":false,"postList_nb_item_per_line":"postList_2_item","postList_nb_max_item":"2","postList_order_by":"none","postList_order_date_which":"acf","postList_order_date_elements":"future","postList_order_date_ordering":"ASC","postList_set_link":true,"postList_link_waz_popup":true,"postList_category_navigation":false,"postList_rub_nav_dropdown":false,"postList_rub_nav_position":"left","postList_rub_nav_all":"Tous les articles","postList_pagination":false,"postList_pagination_nb_posts":12,"postList_pagination_btn_model":false,"postList_pagination_text":"","options":{"animation":false,"animation_delay":0,"animation_element_delay":100,"margin_bottom":"","postList_id":""},"postList_limit_title":"","postList_limit_subtitle":"","postList_limit_description":"","postList_limit_break":"word","postList_limit_add_to_end":"","postList_use_custom_post_type":false,"postList_custom_post_type":"","postList_custom_taxonomy":"","postList_custom_toxonomy_values":"","postList_custom_title":"","postList_custom_subtitle":"","postList_custom_description":"","postList_custom_date":""}

About Edelris

Our DNA

Edelris has continuously been bringing creative solutions to clients and partners from drug discovery organizations for the past 17 years, with a clear focus on Hit generation and Hit-to-Lead optimization. Edelris has pioneered the value of 3D, natural productlike compound collections for HTS and FBLD (Keymical Collections™ and Fragments), and offers successful medicinal chemistry and synthesis of explorative chemical libraries, encoded and non-encoded. Further to this, Edelris differentiates itself with EDEN (Edelris Discovery ENgine) based upon a 2 million proprietary compound collection (Keymical Space™) and AS-MS technologies.

More info at www.edelris.com and LinkedIn.